Symbiotec Pharmalab has successfully raised ₹2,180 crore through its initial public offering (IPO), marking a significant milestone for the company and signaling robust investor confidence in India’s pharmaceutical sector. The capital infusion is expected to support expansion of manufacturing capacity, research and development, and strategic acquisitions, while strengthening the company’s balance sheet.